High glucose reduces cathepsin L activity and impairs invasion of circulating progenitor cells

Carmen Urbich1, Elisabeth Dernbach, Lothar Rössig

  • 1Molecular Cardiology, Department of Internal Medicine III, University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.

Insights

High glucose and diabetes mellitus impair endothelial progenitor cells (EPCs) by reducing cathepsin L activity. This limits EPC invasion and neovascularization, crucial for tissue repair in cardiovascular disease.

Area of Science:

  • Cardiovascular Biology
  • Endothelial Cell Biology
  • Protease Function

Background:

  • Endothelial progenitor cells (EPCs) are vital for neovascularization and repairing damaged blood vessels.
  • Coronary artery disease risk factors, especially diabetes, diminish EPC number and function.
  • Cathepsin L, a cysteine protease, is essential for EPC tissue invasion and neovascularization.

Purpose of the Study:

  • To investigate how high glucose and diabetes mellitus affect EPC invasion and cathepsin L activity.
  • To determine the molecular mechanisms behind altered cathepsin L expression in high glucose conditions.

Main Methods:

  • EPCs were incubated with varying glucose concentrations (10-30 mM).
  • Cathepsin L activity, protein expression, and mRNA levels were measured.
  • EPC invasion and gelatinolytic activity were assessed.
  • EPCs from type 2 diabetic patients and healthy controls were compared.

Main Results:

  • High glucose significantly decreased cathepsin L activity and protein expression in EPCs.
  • Cathepsin L mRNA levels remained unaffected, suggesting post-transcriptional regulation.
  • EPC invasion and gelatinolytic activity were reduced under high glucose conditions.
  • EPCs from diabetic patients showed markedly lower cathepsin L expression and activity.

Conclusions:

  • High glucose and diabetes mellitus impair EPC function by down-regulating cathepsin L.
  • Reduced cathepsin L limits EPCs' matrix-degrading and invasive capabilities.
  • This impairment may compromise the therapeutic potential of EPCs in diabetic patients with cardiovascular disease.